Overview
Part I of this project used Jewish founder populations as a well-documented model for genetic carrier screening. Its central conclusion was that carrier frequency alone is not an adequate guide to screening priority. A condition carried by many people but usually mild, treatable, or variably penetrant should not be treated as equivalent to a less frequent condition that predictably causes early death, severe neurodegeneration, blindness, deafblindness, major organ failure, or lifelong profound disability.
